Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.


Diabetes Drug Account Is Worth $20 Million

By Published on .

NEW YORK (AdAge.com) -- Bayer Corp. is conducting a pitch for a line of products used by diabetes sufferers to measure their glucose levels, which will be rebranded under the Ascensia moniker.

The rebranding is expected to roll out in November.

Five agencies are bidding for the business, according to a Bayer representative, with four having pitched and a fifth doing so this week.

The account is worth $20 million. The representative did not name the agencies.

The Bayer unit, Bayer Diagnostics, is based in Tarrytown, N.Y.

Most Popular